Donald McDonnell, Professor at Department of Pharmacology and Cancer Biology at Duke University School of Medicine, shared a post on LinkedIn:
“Josh Friedman at Healio wrote a very nice piece on the implications of our recent work on androgens/androgen receptor action in prostate cancer.
He also highlighted the clinical studies of Sam Denmeade at Johns Hopkins which support the directions we are taking to develop new drugs for patients with metastatic prostate cancer.
Click here to read more.”
